ArticleBMJ open2020

Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial.

Lin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.